Does a bigger NMN dose raise NAD+ more? In an 80-adult trial, NAD+ was highest at 600 and 900 mg

In a 60-day trial of 80 healthy middle-aged adults, 300, 600 and 900 mg of NMN a day each raised blood NAD+ and six-minute walking distance more than placebo, with the highest NAD+ and the longest walks at 600 and 900 mg (Yi 2023). A 2025 meta-analysis of nine trials in 412 middle-aged and older adults pooled a small improvement in gait speed and a lower liver-enzyme marker (Wang 2025), and a 2026 analysis of the same 80-person trial found a higher blood NAD+ level tracked with a small rise in red-blood-cell count (Kuerec 2026). Results on gait speed are mixed: a second 2025 meta-analysis, in adults over 60, found no effect (Prokopidis 2025).

Does a bigger dose raise NAD+ more?

The question a buyer asks is plain: does a bigger dose give a bigger rise? In a randomized, double-blind, placebo-controlled trial, 80 healthy middle-aged adults took 300, 600 or 900 mg of NMN once a day, or a placebo, for 60 days. Blood NAD+ rose significantly above both baseline and placebo at 30 and 60 days in every dose group (Yi 2023), and it was highest in the 600 and 900 mg groups. Across all three NMN groups, the distance walked in a six-minute test was significantly greater than on placebo at both 30 and 60 days, and longest in the 600 and 900 mg groups. Self-rated general health on the SF-36 survey also improved more than on placebo in all three groups, except the 300 mg group at day 30. Blood biological age stayed unchanged in the NMN groups while it rose in the placebo group, a significant difference, and the supplement was well tolerated, with no safety signal on adverse-event monitoring. The authors conclude the benefit on NAD+ and physical performance peaked at 600 mg a day.

A post-hoc analysis of a double-blind trial in 80 adults aged 40 to 65, on the same three doses for 60 days, asked a sharper question: how much of the NAD+ rise did each person get, and did it track with outcomes? The NAD+ change was dose-dependent, but it varied a lot between individuals, with a within-group coefficient of variation of 29.2 to 113.3 percent. A larger NAD+ change was associated with a longer six-minute walk and a better SF-36 score; the median NAD+ change linked to those gains was 15.7 nmol/L for the walk and 13.5 nmol/L for the SF-36 score (Kuerec 2024). That spread is why “does my dose do anything?” is a personal question: the same pill does not do the same thing for everyone.

For the dose’s effect on metabolism, the same trial measured an insulin-resistance marker and found no difference from placebo at 60 days. So the gains that trial supports are on blood NAD+, walking distance and self-rated health, not on insulin resistance.

What a dose does across the trials

A 2025 meta-analysis pooled nine randomized trials with 412 middle-aged and older adults and found a statistically significant improvement in gait speed (a standardized mean difference of 0.34) and a lower level of the liver-enzyme marker ALT (a standardized mean difference of −0.29), with the strongest effect on an insulin-resistance measure at the smaller doses (Wang 2025). In a randomized, placebo-controlled trial of 60 older adults, 250 mg a day for 12 weeks raised blood NAD+ and its metabolites, gave a shorter 4-meter walk time and better sleep quality than placebo, though the primary stepping test did not differ (Morifuji 2024). In a randomized, double-blind trial of 48 amateur runners who trained five to six times a week, 300, 600 or 1,200 mg a day for six weeks raised oxygen uptake and power at the ventilatory thresholds more at the middle and high doses than placebo, while VO2max, oxygen pulse and peak power did not differ (Liao 2021). And in a 14-day randomized trial of 65 healthy adults, NMN and nicotinamide riboside each raised circulatory NAD+ to a similar degree, while plain nicotinamide did not (Christen 2026).

The pooled results on gait speed disagree. A 2025 meta-analysis of trials in adults with a mean age of 60.9 to 83 found NMN had no significant effect on muscle mass, hand-grip strength, gait speed or the five-time chair stand (Prokopidis 2025). The metabolic results that did appear, insulin sensitivity and signaling in postmenopausal women with prediabetes (Yoshino 2021) and lower body weight, diastolic blood pressure and cholesterol in adults who were overweight or obese on 2,000 mg a day (Pencina 2023), came from specific groups and were not tested in healthy, lean adults, so we will not claim NMN lowers blood sugar or blood pressure for anyone.

How would you know your dose is doing something?

The most direct signal is your own blood NAD+. In a 2026 post-hoc analysis of the same 80-person trial, every 1 nM higher baseline NAD+ was associated with small shifts in the blood, higher lymphocytes and lower neutrophils, and every 1 nM increase in NAD+ during the trial was associated with a small rise in hemoglobin, red-blood-cell count and mean corpuscular hemoglobin concentration, which the authors say potentially indicates enhanced oxygen-carrying capacity. These are associations from one trial, not cause-and-effect (Kuerec 2026).

Because the NAD+ rise varied so much between people on the same dose, the authors of the 2024 analysis say monitoring blood NAD+ can help tailor a personal dose (Kuerec 2024). In the 60-day trial, NAD+ was measured at the start, at day 30 and at day 60 (Yi 2023), so the useful signal is the change from your starting level, not a single reading.

What the evidence does not show

No trial in our evidence compared delivery forms, liposomal, sublingual, enteric or plain, on any outcome, so we cannot say one form raises NAD+ more than another. Morning-versus-evening or with-food-versus-without is also not settled by any human trial we retrieved.

Who should check first

• Pregnant or breastfeeding women, and people under 18, because the trials did not study them.
• People who take prescription medicine, who should check with a clinician first.

The product

NMN Liposomal Capsules give 500 mg of NMN from two capsules a day, with 45 servings. The trials used 250 to 2,000 mg a day, so a 500 mg serving sits inside that range. Renue says NMN is a direct precursor to NAD+, and that its liposomes protect the NMN through digestion for a slower, more sustained release. See NMN Liposomal Capsules